Testing a new way to collect blood samples for liver function
This trial tests a simpler blood collection method for measuring liver function using a substance you drink. It includes healthy people and those with chronic liver disease (like F2-F3 fibrosis or cirrhosis) to see if the new method works as well as standard procedures.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old.
- You are either a healthy person with a body mass index (BMI) between 18 and 25.5, or you have chronic liver disease (including PBC or PSC) with F2 to F3 fibrosis or cirrhosis.
- You are not pregnant.
- You can absorb medicine taken by mouth—meaning you do not have severe stomach emptying problems or have had major small bowel surgery.
- You can drink a thin liquid by mouth and are not restricted from eating or drinking.
- If you have cirrhosis, you have not been in the hospital in the last 3 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests how a drug called D-2570 is processed in people with different levels of liver function. It compares people with liver impairment to those with healthy livers to see how the drug moves through the body.
This study tests a new blood test (HepQuant DuO) to see how well it measures liver function in people with alcohol-related liver disease. If you have liver damage from alcohol and either a recent serious liver flare-up or also a fatty liver condition (NASH), this study may help your doctors understand your liver better.
This study tests new blood tests and MRI scans to see how well your liver works during radiation therapy for liver cancer. It may help doctors better plan treatment and monitor your liver health.
This study uses a simple blood test to look for tiny particles from liver cells. It includes healthy volunteers, people with type 2 diabetes and liver scarring, and people with different stages of liver disease.
This study is looking for new ways to detect liver scarring (fibrosis) in people with fatty liver disease (NAFLD, NASH, MASLD, or MASH). If you qualify, you will give a blood sample to help identify biomarkers that could replace biopsies.
This study looks at how the medicine PF-07328948 is processed by people with different levels of liver function. It includes both healthy people and those with stable liver disease (classified as mild, moderate, or severe). The goal is to see if the liver condition affects how the drug works in the body.
Hear when a new Healthy Adult Participants trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.